MAP - Market Access Podcast Podcast Por Dr. Stefan Walzer arte de portada

MAP - Market Access Podcast

MAP - Market Access Podcast

De: Dr. Stefan Walzer
Escúchala gratis

Market Access (or alternatively reimbursement) in health care is THE key competence in order to be commercially successful with a new drug, medical device or digital health application. However, given the fact that market access is a complex field involving various disciplines and is an ever-changing field, it is difficult to be up to speed with the different evolvements across the world. MAP is THE bi-weekly Market Access Podcast provided by MArS Market Access & Pricing Strategy, which is your health care consultancy in the German-speaking markets and allows you to keep up to date with market access , reimbursement and pricing issues in the D-A-CH countries and around the world. With MAP you will get a summary of core market access systems and processes as well as latest changes in regulations including statements and opinions of core decision makers and stakeholders from various countries. The CEO and founder of MArS is also the driver behind MAP: Dr. Stefan Walzer works in the field of payer strategy, pricing, health economics and reimbursement since 2004 and is the founder and CEO of MArS Market Access & Pricing Strategy GmbH based in Germany. MArS makes it as easy as possible for you to get your Pharmaceutical, MedTech or digital health product to the market and of course get the price it deserves. Stefan previously worked as a payer consultant for various global pharmaceutical and medical device / diagnostic companies, successfully launching their products across the world. He was the Global Payer Strategy Leader for various products and compounds at F. Hoffmann – La Roche AG, where he successfully developed early payer strategies as well as launching and maintaining the reimbursement process for top brands and early compounds. Stefan is capable in translating the clinical and economic evidence into successful reimbursement submissions and pricing negotiations especially in Austria, Germany and Switzerland. Additionally he teaches market access, pricing and negotiations at the State University of Baden-Wuerttemberg and the University of Applied Sciences Weingarten-Ravensburg (both Germany). Besides other roles and responsibilities. Stefan was the head of the committee “Inpatient care” of the German Health Economic Association (DGGÖ). Furthermore he is also a member of the Austrian Health Economic Association (ATHEA) and the Swiss Health Economic Association (SGGÖ). Additionally, he is a member of the Access Advisory Committee of the Global Pneumonia Prevention Coalition. Stefan received a Master of Science in Economics from the University of Tuebingen (Germany), a PhD in Health Economics from the University of Zurich (Switzerland) and a post-graduate diploma in Clinical Trials from the London School of Hygiene and Tropical Medicine (UK). He is co-author of more than 40 peer-reviewed scientific articles and more than 300 scientific abstracts.Copyright 2026 Dr. Stefan Walzer Ciencia Economía Enfermedades Físicas Higiene y Vida Saludable
Episodios
  • Continuous Insight, Not One-Off Studies: Are Primary Research Platforms Defining a New Era, Shrutya Bhalla?

    Continuous Insight, Not One-Off Studies: Are Primary Research Platforms Defining a New Era, Shrutya Bhalla?
    Apr 15 2026

    In the latest episode of the MAP – Market Access Podcast, Dr. Stefan Walzer speaks with pricing and access expert Shrutya Bhalla about how primary research must evolve in an era of AI, policy shocks, and accelerating market complexity. The key takeaway: high‑quality primary research is no longer just about collecting insights – it must enable real strategic choices on pricing, access, launch sequencing, and evidence generation. This means moving from slow, static projects to continuous, platform‑driven, AI‑supported research, using AI for speed, automation and better hypotheses while keeping humans firmly in the lead for judgment, context and responsibility, and building research that is robust enough for MFN, new US tariffs, and fast‑changing global policy environments.

    Shrutya also shares how new stakeholder research platforms like Mulya, and innovations such as Market Access 4.0 tools like mAxInsights, DO-Bo, Q-Bo and Wafle, are redefining how we run payer research: faster, more economical, and closer to real‑time decision needs. If you work in market access, pricing, Health Economics and Outcomes Research (HEOR) or commercialization, this episode is a must‑listen to understand where primary research is headed.

    Stay connected by subscribing on your favorite podcast platform or listening directly on our website: MAP Podcasts —and if you enjoyed the episode, don’t forget to rate it and the podcast!

    MAP is the first and only bi-weekly market access podcast provided by MArS—and the global #1 podcast in the field of health economics. For more information about MArS Market Access and Pricing Strategy, visit: https://marketaccess4-0.com/

    #MarketAccess #PricingAndReimbursement #PrimaryResearch #GlobalHealth #Mulya #mAxInsights #DO-Bo #Q-Bo #Wafle #Pharma #AIinHealthcare #PayerInsights #CommercialStrategy #MAPPodcast #marketaccess #marketaccesspodcast
    Más Menos
    39 m
  • How Can Political Leadership Turn Health into an Economic Priority, Hatice Küçük Benton?

    How Can Political Leadership Turn Health into an Economic Priority, Hatice Küçük Benton?
    Apr 1 2026

    In this episode of the MAP – Market Access Podcast, Dr. Stefan Walzer speaks with Hatice Küçük Beton, Executive Director of the G20 Health and Development Partnership, about how to make global health truly investable – and keep it on the political agenda once the immediate crisis fades. They explore why high-level leadership, from Angela Merkel’s role during Germany’s G20 presidency to Japan’s joint health–finance initiative, was crucial in moving health from a “social cost” to a strategic economic and security issue. Hatice explains how bringing health and finance ministers to the same table – and getting them to speak the same financial language – has begun to reshape thinking around budgets, risk and long‑term system resilience.

    The conversation then dives into what a practical health investment framework could look like, with clear positive qualifiers, benchmarks and disqualifiers to guide capital into high-impact areas without overburdening investors with new bureaucracy. Hatice and Stefan discuss why health must be de‑politicised and reframed as a pillar of economic resilience, geopolitical security and human wellbeing – not a “nice to have” public service – and why returns on health investments should not be taboo. If you work in market access, health economics, policy, pharma, medtech or healthcare investment, this episode offers concrete ideas on how smarter, market‑driven health investment can shape global and national health systems by 2030.

    Stay connected by subscribing on your favorite podcast platform or listening directly on our website: MAP Podcasts —and if you enjoyed the episode, don’t forget to rate it and the podcast!

    MAP is the first and only bi-weekly market access podcast provided by MArS—and the global #1 podcast in the field of health economics. For more information about MArS Market Access and Pricing Strategy, visit: https://marketaccess4-0.com/

    #MarketAccess #GlobalHealth #G20 #HealthEconomics #HealthInvestment #HealthFinancing #HealthPolicy #HealthcareFinance #G20Health #ImpactInvesting #marketaccess #marketaccesspodcast
    Más Menos
    41 m
  • Is Europe Still More Attractive Than the US, China, India or MENA for Medtech Investment, Bernard Bichsel?

    Is Europe Still More Attractive Than the US, China, India or MENA for Medtech Investment, Bernard Bichsel?
    Mar 15 2026

    In the latest Market Access Podcast episode, host Stefan Walzer sits down with Bernard “Bernie” Bichsel – one of Europe’s most experienced voices in medtech regulation and former Head of the Medical Devices Division at Swissmedic – to unpack how regulation and market access truly fit together. They discuss why medical device regulation in Europe is still young compared to pharma, why the MDR/IVDR “notified body bottleneck” is largely yesterday’s problem, and how smart startups build regulatory timelines, costs, and clinical evidence into their plans from day one.

    They then zoom out to Omnibus, the AI Act, and geopolitics, and what all of this means for the attractiveness of Europe vs. the US, China, India, and the rapidly growing Arabic region as medtech markets. Despite the challenges, Europe still offers world‑class innovation, strong universities, and a powerful SME ecosystem – and remains a key region for medtech investment. If you’re a medtech founder, regulatory lead, or market access professional, this episode will help you rethink when and how you integrate regulation and reimbursement into your strategy.

    Stay connected by subscribing on your favorite podcast platform or listening directly on our website: MAP Podcasts —and if you enjoyed the episode, don’t forget to rate it and the podcast!

    MAP is the first and only bi-weekly market access podcast provided by MArS—and the global #1 podcast in the field of health economics. For more information about MArS Market Access and Pricing Strategy, visit: https://marketaccess4-0.com/

    #MarketAccess #MedTech #MDR #IVDR #RegulatoryAffairs #HealthEconomics #medtech #medtechregulation #Reimbursement #Startups #EUHealthcare #marketaccess #marketaccesspodcast
    Más Menos
    35 m
Todavía no hay opiniones